Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder

BACKGROUND: Meta-analysis data demonstrate a 5% absolute survival benefit for neoadjuvant chemotherapy (NAC) using cisplatin-based combination regimens in the radical treatment of muscle-invasive bladder cancer (MIBC). However, there are no randomized, controlled trial data on the optimum regimen. A...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Blick, C, Hall, P, Pwint, T, Al-Terkait, F, Crew, J, Powles, T, Macaulay, V, Munro, N, Douglas, D, Kilbey, N, Protheroe, A, Chester, J
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	2012

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. gan Blick, C, Hall, P, Pwint, T, Al-Terkait, F, Crew, J, Powles, T, Macaulay, V, Munro, N, Douglas, D, Kilbey, N, Protheroe, A, Chester, J

Cyhoeddwyd 2012

Journal article

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder

Eitemau Tebyg